pharma · Growth Hormone Deficiency, Pediatric
Ascendis Pharma
Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma patent portfolio — 6 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Palo Alto, USA
- Founded
- 2010
- Employees
- 5
- Programs
- 2
- Drugs
- 7
- Patents
- 6
Ascendis Pharma patents
6 pharmaceutical patents indexed for Ascendis Pharma. 0 expire within 24 months.
Ascendis Pharma has 6 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 2025295738
Long-Acting Growth Hormone Dosage Forms With Superior Efficacy to Daily Somatropin
granted -
CA 3131817
FORMES POSOLOGIQUES D'HORMONE DE CROISSANCE A ACTION PROLONGEE AYANT UNE EFFICACITE SUPERIEURE A UNE DOSE DE SOMATROPINE QUOTIDIENNE
granted -
US 2017354716
Novel Polymeric hGH Prodrugs
granted -
US 2017312342
Long-Acting Growth Hormone Dosage Forms
granted -
US 2017056477
Dry Growth Hormone Composition Transiently Linked to a Polymer Carrier
granted -
US 2016206702
PEGylated Recombinant Human Growth Hormone Compounds
granted
Frequently asked questions
How many patents does Ascendis Pharma have?
6 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Ascendis Pharma patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.